stockrowNovartis AG
NVS Healthcare Drug Manufacturers General
Novartis AG’s revenue for fiscal 2025 (year ended December 2025) was $56.7 billion, up 9.57% from fiscal 2024.
- Revenue
- +4.67%
- EPS
- −69.1%
- Free cash flow
- −17.8%
- Total debt
- +53.9%
Quarter to September 2026, against a year earlier
Follow NVS
Alert me
Novartis AG (NVS) EPS (diluted)
Novartis AG's EPS (diluted) for fiscal 2025 was $7.15, up 21.8% from $5.87 in fiscal 2024. Over the twelve months to 30 September 2026 it was $5.24. Over the past ten years it has ranged from $2.80 (fiscal 2016) to $10.63 (fiscal 2021); the current reading is higher than 82% of that period. Novartis AG ranks 6th of 20 Drug Manufacturers General companies by EPS (diluted).
EPS (diluted), annual
Embed this chart
Annual newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| FY2025 | $7.15 | 21.81% |
| FY2024 | $5.87 | (17.90%) |
| FY2023 | $7.15 | 125.55% |
| FY2022 | $3.17 | (70.18%) |
| FY2021 | $10.63 | 201.99% |
| FY2020 | $3.52 | (30.43%) |
| FY2019 | $5.06 | (5.95%) |
| FY2018 | $5.38 | 65.54% |
| FY2017 | $3.25 | 16.07% |
| FY2016 | $2.80 | (61.59%) |
Quarterly newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| Sep 2026 | $0.63 | (63.29%) |
| Jun 2026 | $1.71 | 3.64% |
| Mar 2026 | $1.65 | 32.00% |
| Dec 2025 | $1.25 | (38.12%) |
| 43 more quarters | Free account |
Against its own ten years
EPS (diluted) against peers
| Company | EPS (diluted) |
|---|---|
| AMGN Amgen Inc. compare | $17.24 |
| AZN AstraZeneca PLC compare | $7.06 |
| JNJ Johnson & Johnson compare | $6.60 |
| ABBV AbbVie Inc. compare | $5.81 |
| NVS Novartis AG | $5.24 |
| NVO Novo Nordisk A/S compare | $4.09 |
| MRK Merck & Co., Inc. compare | $0.97 |
| PFE Pfizer Inc. compare | $0.71 |
| GILD Gilead Sciences, Inc. compare | −$3.16 |
What EPS (diluted) is
Diluted EPS tells an investor how much profit a company earned for each share, counting the extra shares that options and convertible securities could create.
Reported line item
More on NVS
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement